Intravitreal Anti-Vascular Endothelial Growth Factor Use in France During the Coronavirus Disease 2019 Pandemic

JAMA Ophthalmol. 2021 Feb 1;139(2):240-242. doi: 10.1001/jamaophthalmol.2020.5594.

Abstract

This cohort study uses data from the French National Health Data System to assess the decline in the use of intravitreal anti–vascular endothelial growth factors before, during, and after pandemic-associated lockdown periods.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Angiogenesis Inhibitors / therapeutic use*
  • COVID-19 / epidemiology*
  • Drug Utilization / statistics & numerical data*
  • Female
  • France / epidemiology
  • Health Services Accessibility
  • Humans
  • Intravitreal Injections
  • Male
  • Quarantine
  • Ranibizumab / therapeutic use
  • Receptors, Vascular Endothelial Growth Factor / therapeutic use
  • Recombinant Fusion Proteins / therapeutic use
  • Retinal Diseases / drug therapy
  • Retrospective Studies
  • SARS-CoV-2*
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors*

Substances

  • Angiogenesis Inhibitors
  • Recombinant Fusion Proteins
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • aflibercept
  • Receptors, Vascular Endothelial Growth Factor
  • Ranibizumab